Popular Articles on Diabetesnet.com
When you were diagnosed, you were probably told you had either Type 1 or Type 2 diabetes. Clear-cut and tidy. Since diabetes typically occurs in two types, you have to fit into one of them. Many people fit clearly into one of these categories, but others do not. And those who clearly fit one type when diagnosed may find these clear lines begin to smudge over time. Are there really only two types? Are you really the type you were told you were? Could you have more than one type of diabetes?
The most common types of diabetes are type 1 and type 2 diabetes. Along with gestational and LADA, these forms of diabetes are polygenic diseases that require the involvement of many genes and a wide variety of environmental factors to cause each disease. There are some rare forms of diabetes, Maturity Onset Diabetes of the Young (MODY) and Neonatal Diabetes Mellitus (NDM) that are monogenic where only one gene is responsible for the disease. Of the 30,000 genes in the human body, about 20 genes have been linked to monogenic diabetes so far.
Lantus and Levemir are long-acting insulins that supply the background insulin needed to supply cells with glucose around the clock while preventing release of excess glucose from the liver and excess fat from fat cells. The waking glucose level best measures the activity of these insulins. All Type 1s and many Type 2s also require a faster insulin (Humalog, Novolog, or Apidra) to cover meals and lower any high glucose.
The Animas Vibe is an insulin pump with a built in Dexcom Continuous Glucose Monitor. Although there is a pump-only version of the Vibe available, the combination of the pump and monitor are what makes the Vibe stand out. The Vibe, alone, is basically the Animas 2020 pump platform from a few years ago.
The Vibe has been available in the UK since 2011. Johnson & Johnson finally submitted the Animas Vibe to the FDA in April of 2013.
The Henne Group is currently looking for adult men and women with a clinical diagnosis of Diabetic Kidney Disease. They will conduct hour long in-person interviews with people from different cities across the United States to elicit patients’ experiences with DKD, including time of diagnosis, symptoms, & treatment history. Those interviewed will receive $100 as a thank you and compensation for their time. No attempt will be made to sell anything or influence your thinking, and all participation is confidential. Those interested in being a part of this study call 415-348-2986 or 877-737-5782 ext 286 or complete a screener online.